Fierce

Fierce Whiskers Launches World's First Carbon-Negative Bourbon

Retrieved on: 
Friday, September 23, 2022

AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter, a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas. Five O'Clock Shadow, a single-barrel bourbon release dropping exclusively at the company's first-anniversary event on September 24, 2022, also represents the first bourbon release for this grain-to-grass distillery.

Key Points: 
  • CarbonBetter today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter , a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • "At Fierce Whiskers, we are singularly focused on making the best possible whiskey in Austin, Texas.
  • The work to measure, reduce, and report on Fierce Whiskers' impacts set the stage to release a carbon-negative bourbon by leveraging carbon intensity calculations.

Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20

Retrieved on: 
Wednesday, September 14, 2022

Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPharma, will meet a broad scope of players in the biotech space regarding the Companys pipeline of signature cancer-fighting treatments.

Key Points: 
  • Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPharma, will meet a broad scope of players in the biotech space regarding the Companys pipeline of signature cancer-fighting treatments.
  • TheFierce Biotech Summitis a two-day conference covering drug development from the earliest stage of research to FDA approval.
  • The event is organized by the editors of Fierce Biotech and is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies.
  • Hillstream intends to start a clinical study with HSB-1216 in 2022 to expand upon the existing early clinical proof-of-concept.

IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform

Retrieved on: 
Tuesday, September 13, 2022

With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.

Key Points: 
  • With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.
  • The researchers observed that in mice treated with CAR-T cells, cytokine expression measured with IsoPlexis CodePlex platform suggested that IL-7 secretion promoted a Th1 functional phenotype to drive anti-tumor activity more effectively.
  • This initial data generated using IsoPlexis CodePlex solution indicates that the platform can provide key insights into cytokine signatures of CAR-T products to characterize function for improved persistence and potency.
  • This first APAC publication validates IsoPlexis' platform as a powerful tool that provides customers with a new layer of proteomic information, said Jason Ou, President/General Manager, APAC Region at IsoPlexis.

Fierce Conversations Introduces Pulse by Fierce, A Revolutionary New App That Helps Employees Reduce Workplace Stress and Anxiety

Retrieved on: 
Monday, September 12, 2022

SEATTLE, Sept. 12, 2022 /PRNewswire/ -- Fierce Conversations, a Seattle-based leadership development organization, announced today the launch Pulse by Fierce, an app designed to effectively reduce employee stress and anxiety while improving their resilience levels at work. Pulse enables businesses to identify and eliminate stress factors by using a combination of patented technology, breakthrough stress-management research, and interactive content and coaching.

Key Points: 
  • Pulse enables businesses to identify and eliminate stress factors by using a combination of patented technology, breakthrough stress-management research, and interactive content and coaching.
  • Pulse monitors an employee's individual stress and Heart Rate Variability (HRV) to objectively measure stress levels.
  • By associating stress triggers to specific times and events, the app can identify root causes for an employee's anxiety.
  • "Pulse is going to make a huge impact on that loss by giving employees a new level of self-awareness about their stress triggers and tools to counteract that stress."

Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022

Retrieved on: 
Monday, September 12, 2022

Agomab Therapeutics NV (Agomab) today announced that Fierce Biotech has named the company as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Key Points: 
  • Agomab Therapeutics NV (Agomab) today announced that Fierce Biotech has named the company as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
  • The Fierce 15 award is a great endorsement of our teams groundbreaking work and we are thrilled to join an outstanding group of companies that Fierce sees as the up-and-coming vanguard for our industry.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Fierce Biotech Names Synthekine as One of Its “Fierce 15” Biotech Companies of 2022

Retrieved on: 
Monday, September 12, 2022

Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Key Points: 
  • Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
  • I am particularly proud of the substantial progress our talented and dedicated team has made in the three years since Synthekine was founded.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022

Retrieved on: 
Monday, September 12, 2022

Scorpion Therapeutics, Inc. (Scorpion), a pioneering oncology company redefining the frontier of precision medicine, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Key Points: 
  • Scorpion Therapeutics, Inc. (Scorpion), a pioneering oncology company redefining the frontier of precision medicine, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
  • Everyone at Scorpion is delighted to be selected as a Fierce 15 company from a pool of many worthy candidates.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Fierce Biotech names STORM Therapeutics as one of its "Fierce 15" Biotech Companies of 2022

Retrieved on: 
Monday, September 12, 2022

CAMBRIDGE, England, Sept. 12, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes for oncology and other diseases, is pleased to announce that Fierce Biotech has named it as one of its 2022 "Fierce 15", designating it as one of the most exciting biotechnology companies in the industry. This award highlights STORM's dedication to developing novel treatments for the unmet medical need of patients, and its successes at the forefront of the RNA modification field.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics added:"We are thrilled to be named among the industry's most exciting biotech companies.
  • The Fierce 15 awards celebrate the spirit of being "fierce" championing innovation and creativity, even in the face of intense competition.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Fierce Biotech names STORM Therapeutics as one of its "Fierce 15" Biotech Companies of 2022

Retrieved on: 
Monday, September 12, 2022

CAMBRIDGE, England, Sept. 12, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes for oncology and other diseases, is pleased to announce that Fierce Biotech has named it as one of its 2022 "Fierce 15", designating it as one of the most exciting biotechnology companies in the industry. This award highlights STORM's dedication to developing novel treatments for the unmet medical need of patients, and its successes at the forefront of the RNA modification field.

Key Points: 
  • Dr. Jerry McMahon, CEO of STORM Therapeutics added:"We are thrilled to be named among the industry's most exciting biotech companies.
  • The Fierce 15 awards celebrate the spirit of being "fierce" championing innovation and creativity, even in the face of intense competition.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Fierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company

Retrieved on: 
Monday, September 12, 2022

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Fierce Biotech named it as a 2022 Fierce 15 recipient, a recognition given to the biopharmaceutical industrys most promising early-stage companies.

Key Points: 
  • Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Fierce Biotech named it as a 2022 Fierce 15 recipient, a recognition given to the biopharmaceutical industrys most promising early-stage companies.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.